---
figid: PMC9684170__fimmu-13-1016730-g003
pmcid: PMC9684170
image_filename: fimmu-13-1016730-g003.jpg
figure_link: /pmc/articles/PMC9684170/figure/f3/
number: Figure 3
figure_title: ''
caption: The mechanisms involved in non-allergic hypersensitivity reactions to small
  molecule drugs. (A) Direct activation of mast cells. (B) Activation of complement.
  (C) Inhibition of cyclooxygenases. (D) Elevation of bradykinin. (E) Activation of
  the RhoA/ROCK signaling pathway. ER, endoplasmic reticulum; MRGPRX2, Mas-related
  G protein-coupled receptor X2; PLCγ, phospholipase C gamma; IP3, inositol triphosphate;
  IP3R, inositol triphosphate receptor; PKC, protein kinase C; P38, p38(MAPK) pathway;
  MAC, membrane attack complex; 12-/15-/5-HETEs, 12-/15-/5-hydroxy eicosatetraenoic
  acids; 12-/15-/5-HPETE, 12-/15-/5-hydroperoxyeicosatetraenoic acid; LTA4/LTB4/LTC4/LTD4/LTE4,
  leukotriene A4/B4/C4/D4/E4; PGG2/PGI2/PGE2/PGE2a/PGD2, prostaglandin G2/I2/E2/E2a/D2;
  TXA2, thromboxane A2; BKR-2, bradykinin receptor type 2; JAK, Janus-activated kinase;
  STAT3, signal transducer and activator of transcription 3; DAG, diacylglycerol;
  eNOS, endothelial nitric oxide synthase; NO, nitric oxide; PLA2, phospholipase A2;
  PGs, prostaglandins; LTs, leukotrienes; GDP-Rho A, an inactive GDP-bound Ras homolog
  family member A; GTP-Rho A, an active GTP-bound Ras homolog family member A; ROCK,
  Rho-associated kinase; MLC, myosin light chain; p-MLC, phospho-myosin light chain;
  MLCP, myosin light chain phosphatase.
article_title: Hypersensitivity reactions to small molecule drugs.
citation: Jiayin Han, et al. Front Immunol. 2022;13:1016730.
year: '2022'

doi: 10.3389/fimmu.2022.1016730
journal_title: Frontiers in Immunology
journal_nlm_ta: Front Immunol
publisher_name: Frontiers Media S.A.

keywords:
- drug hypersensitivity reactions
- small molecule drugs
- allergic drug hypersensitivity reactions
- non-allergic drug hypersensitivity reactions
- screening hypersensitivity reactions in clinical practice
- hypersensitivity evaluation for investigational new drugs or post-marketing drugs

---
